Carl Wilhelm Vogel

• Former Director of Cancer Research Center of Hawaii at the University of Hawaii
• Prof. em at the University of Hawaiʻi Cancer Center, Honolulu, USA

Dr. Vogel has over four decades of expertise in the human complement system, focusing on C3 and cobra venom factor (CVF), a structural analog of activated C3. He and colleagues developed a human C3 derivative, "humanized CVF" (hCVF, later iC3), capable of depleting complement both in vitro and in vivo. This novel therapeutic shows promise for diseases involving complement, such as AMD, myasthenia gravis, myocardial infarction, arthritis, PNH, and hemophilia. His work has led to two biotech companies, Incode Inc. (1986) and iC3 LLC (2018), and recombinant CVF is commercially available for research.